Journal
JOURNAL OF INHERITED METABOLIC DISEASE
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/jimd.12626
Keywords
AAV; ex vivo; gene therapy; in vivo; lentiviral vectors; mucopolysaccharidosis
Ask authors/readers for more resources
Current treatments for mucopolysaccharidoses (MPSs), including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), have limitations such as lack of effectiveness on brain and skeletal manifestations, lifelong injections, and high costs. Gene therapy in MPSs aims to achieve high levels of the therapeutic enzyme through gene-modified stem cells or viral vector infusion. This review discusses the recent clinical progress and various gene therapy approaches for MPSs.
Current specific treatments for mucopolysaccharidoses (MPSs) include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT). Both treatments are hampered by several limitations, including lack of efficacy on brain and skeletal manifestations, need for lifelong injections, and high costs. Therefore, more effective treatments are needed. Gene therapy in MPSs is aimed at obtaining high levels of the therapeutic enzyme in multiple tissues either by engrafted gene-modified hematopoietic stem progenitor cells (ex vivo) or by direct infusion of a viral vector expressing the therapeutic gene (in vivo). This review focuses on the most recent clinical progress in gene therapies for MPSs. The various gene therapy approaches with their strengths and limitations are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available